SEEDS

Seeds continue to be utilised in his practice with outstanding results in the appropriately chosen patients. Generally, these patients are people with a low-risk prostate cancer, with minimal urinary symptoms, in middle-age, particularly those wanting a less invasive form of therapy and a very rapid recovery.

Recently he did a review of his cases where there was at least a two-year follow-up and up to 14 year follow up.. In looking at over 500 of his cases the results were as follows:

  • Cancer-specific survival 100%.
  • Local recurrence 3%.
  • Urinary incontinence (mild) 1%.
  • Erectile dysfunction 30%.

Ideal patients - Gleason 3 + 3 or Gleason 3 + 4 cancer with 50% of the biopsies cores tended to fare less well. Furthermore, patients with PSAs of >15 or patients with Gleason >3 + 4, also did not do as well with seed therapy alone (see Table 1).

SEEDS results

Seed therapy therefore remains an excellent option for middle-aged patients with low-risk or intermediate-risk low-volume disease in patients wishing a less invasive treatment option and a rapid recovery.

 

About Phillip

Phillip is the Chairman of the Department of Urology, St Vincent's Private Hospital and Clinic since 2003, and a Director of the St Vincent's Prostate Cancer Centre.

The Australian Prostate Cancer Research Centre in New South Wales recently appointed him as clinical director. He is also a member of the National Prostate Cancer Research Centre

Philip is currently the highest volume robotic surgeon in Australasia

He is perhaps best known for his work developing nerve sparing techniques to help patients maximise potency